Shares of Acumen Pharmaceuticals, Inc. (ABOS) surged over 100 percent in the early morning trade on Monday after the firm declared positive top line results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomer or AßO targeting antibody therapy in early Alzheimer's disease.
Apple is focused on its ambitious Apple 2030 goal to be carbon neutral for every product. To help achieve this, more than 250 global manufacturing partners including 12 operating in India have already committed to 100 percent renewable energy for all Apple production by 2030.